Stakeholder Insight: HIV

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-10-14

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

HIV is now considered a chronic, manageable disease. However the lifelong therapy required to control HIV means considerations such as patient quality of life and cost of therapy are becoming increasingly influential in product choice. Consequently the development of new products which offer limited improvements in efficacy but better convenience and tolerability has changed prescription practices


Scope

  • Analysis of current treatment regimens and unmet needs, based on a survey of 180 physicians in the seven major pharma markets around the world
  • Current epidemiology of HIV in the seven major markets, including prevalence, age and gender splits, with analysis of diagnosis and chain of care
  • A detailed examination of the numbers of patients on each line of therapy, which drugs they are taking and for what reasons is provided
  • An assessment of key unmet needs within HIV and the changes in mortality since the introduction of HAART is included


    • Report Highlights
    Increasing transmission by heterosexual contact suggests both an absence and/or ineffectiveness of HIV awareness and education programs. It also exposes more females to the HIV virus, leading to unique disease management issues.

    The success of HAART in prolonging survival within the HIV population introduces new psychosocial challenges beyond pharmaceutical management. Age-related conditions, comorbidities and the desire to conceive call for a new multi-faceted pattern of patient care

    Datamonitor physician research indicates that of 273,000 first-line treated individuals, globally 79% are now receiving fixed dosed combinations (FDCs). While guidelines and HIV specialists have embraced their convenience and simplicity, the unstructured nature of later lines of therapy requires increasing individualization


    Reasons to Purchase

  • Understand the unique disease management issues raised by increasing heterosexual transmission of HIV to females
  • Identify opportunities for new patterns of patient care following the success of HAART in prolonging survival
  • Explore unmet needs in HIV therapy, as identified by treating physicians, and including increased individualization in later-line therapy

    • Table of Contents

    Other users found this report page using the following search terms: hiv ccr5 integrase haart hiv stakeholder opinion uk key leader insight allintitle treatment germany

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.